Recursion Pharmaceuticals, Inc.
RXRX
$4.54
$0.225.10%
NASDAQ
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -73.08% | 30.37% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -73.08% | 30.37% | |||
| Cost of Revenue | -8.77% | -1.76% | |||
| Gross Profit | -0.77% | 5.23% | |||
| SG&A Expenses | -10.77% | -14.63% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.25% | -5.17% | |||
| Operating Income | 2.28% | 7.91% | |||
| Income Before Tax | 5.61% | 15.17% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 5.61% | 15.11% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 5.61% | 15.11% | |||
| EBIT | 2.28% | 7.91% | |||
| EBITDA | 0.80% | 11.43% | |||
| EPS Basic | 11.87% | 18.06% | |||
| Normalized Basic EPS | 11.85% | 18.16% | |||
| EPS Diluted | 11.87% | 18.06% | |||
| Normalized Diluted EPS | 11.85% | 18.16% | |||
| Average Basic Shares Outstanding | 7.10% | 3.62% | |||
| Average Diluted Shares Outstanding | 7.10% | 3.62% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||